Cargando…

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib

Fibroblast growth factor receptor (FGFR) gene alterations are relatively frequent in lung squamous cell carcinoma (LSCC) and are a potential targets for therapy with FGFR inhibitors. However, little is known regarding the clinicopathologic features associated with FGFR alterations. The angiokinase i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hibi, Masaaki, Kaneda, Hiroyasu, Tanizaki, Junko, Sakai, Kazuko, Togashi, Yosuke, Terashima, Masato, De Velasco, Marco Antonio, Fujita, Yoshihiko, Banno, Eri, Nakamura, Yu, Takeda, Masayuki, Ito, Akihiko, Mitsudomi, Tetsuya, Nakagawa, Kazuhiko, Okamoto, Isamu, Nishio, Kazuto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132273/ https://www.ncbi.nlm.nih.gov/pubmed/27581340 http://dx.doi.org/10.1111/cas.13071

Ejemplares similares

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Targeting MET Amplification as a New Oncogenic Driver
por: Kawakami, Hisato, et al.
Publicado: (2014)

MEK inhibitors against MET-amplified non-small cell lung cancer
por: Chiba, Masato, et al.
Publicado: (2016)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
por: Lin, Tong, et al.
Publicado: (2017)

Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer
por: Englinger, Bernhard, et al.
Publicado: (2017)

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
por: Chiba, Masato, et al.
Publicado: (2017)

Clinical development of nintedanib for advanced non-small-cell lung cancer
por: Takeda, Masayuki, et al.
Publicado: (2015)

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer
por: Watanabe, Satomi, et al.
Publicado: (2018)

Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter
por: SAKAI, KAZUKO, et al.
Publicado: (2015)

Clinical and immune profiling for cancer of unknown primary site
por: Haratani, Koji, et al.
Publicado: (2019)

KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival
por: Terashima, Masato, et al.
Publicado: (2014)

SRPX2 Is a Novel Chondroitin Sulfate Proteoglycan That Is Overexpressed in Gastrointestinal Cancer
por: Tanaka, Kaoru, et al.
Publicado: (2012)

A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018)

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
por: Sakai, Kazuko, et al.
Publicado: (2015)

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
por: Takeda, Masayuki, et al.
Publicado: (2018)

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts
por: Kato, Ryoji, et al.
Publicado: (2020)

The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
por: Kanemura, Hiroaki, et al.
Publicado: (2022)

Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer
por: Sakai, Kazuko, et al.
Publicado: (2015)

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer
por: Togashi, Yosuke, et al.
Publicado: (2014)

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
por: Terashima, Masato, et al.
Publicado: (2014)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition
por: KOGITA, AKIHIRO, et al.
Publicado: (2014)

Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples
por: Ishii, Hidenobu, et al.
Publicado: (2015)

MET amplification as a potential therapeutic target in gastric cancer
por: Kawakami, Hisato, et al.
Publicado: (2012)

Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production
por: Togashi, Yosuke, et al.
Publicado: (2013)

Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment
por: Kaneda, Hiroyasu, et al.
Publicado: (2013)

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
por: KATO, HIROAKI, et al.
Publicado: (2013)

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
por: Togashi, Yosuke, et al.
Publicado: (2014)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
por: Azuma, Koichi, et al.
Publicado: (2016)

Performance of Oncomine Fusion Transcript kit for formalin‐fixed, paraffin‐embedded lung cancer specimens
por: Sakai, Kazuko, et al.
Publicado: (2019)

Melanoma Transition Is Frequently Accompanied by a Loss of Cytoglobin Expression in Melanocytes: A Novel Expression Site of Cytoglobin
por: Fujita, Yoshihiko, et al.
Publicado: (2014)

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours
por: Liu, Juan, et al.
Publicado: (2022)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

Nintedanib-Induced Renal Thrombotic Microangiopathy
por: Fujita, Takeshi, et al.
Publicado: (2021)

Aggressive pulmonary adenocarcinoma with new FGFR translocation and cMET mutation not responsive to crizotinib and nintedanib treatment: a case report
por: Svaton, Martin, et al.
Publicado: (2020)

Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression
por: Sato, Katsuaki, et al.
Publicado: (2016)

Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib
por: Mizuuchi, Hiroshi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h9i529vp1vtlevlqsgkq18mqm0